GDC-0032

DRUG5 trials

Sponsors

Genentech, Inc., The Netherlands Cancer Institute

Conditions

Breast CancerBreast Cancer, Non-small Lung CancerHealthy VolunteerNon-Hodgkin's LymphomaSolid Cancers

Phase 1

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

TerminatedNCT01296555

Genentech, Inc.Non-Hodgkin's Lymphoma, Solid Cancers

Start: 2011-03-16End: 2021-06-25Updated: 2024-07-31

A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers

CompletedNCT01814709

Genentech, Inc.Healthy Volunteer

Start: 2013-04-30End: 2013-08-31Updated: 2016-11-02

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

CompletedNCT01862081

Genentech, Inc.Breast Cancer, Non-small Lung Cancer

Start: 2013-07-16End: 2017-06-09Updated: 2017-11-28

A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers

CompletedNCT01967966

Genentech, Inc.Healthy Volunteer

Start: 2013-11-30End: 2013-12-31Updated: 2016-11-02

Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen

CompletedNCT02285179

The Netherlands Cancer InstituteBreast Cancer

Start: 2014-11-30End: 2022-05-01Updated: 2022-10-12

Related Papers

Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer.

2024-06-27

A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.

2019-07-314 citations

Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in <i>PIK3CA</i>-mutated locally advanced or metastatic solid tumors

Cancer Research2018-07-016 citations

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Cancer Research2017-02-153 citations

Abstract P6-12-01: Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by <i>PIK3CA</i> and <i>ESR1</i> mutation status from circulating tumor DNA

Cancer Research2017-02-152 citations

POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA.

Journal of Clinical Oncology2016-05-207 citations

Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic <i>PIK3CA</i> mutant solid tumor types.

Journal of Clinical Oncology2016-05-20